Recon: DoJ subpoenas BioMarin over sponsored testing programs; Boehringer, Zealand’s weight loss drug shows promise in mid-stage MASH study

• BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies (Reuters)
• Oregon suspends a portion of its drug transparency law found to be unconstitutional (STAT)
• Amgen’s rheumatoid arthritis drug Enbrel targeted for first-in-the-nation price limit in Colorado (STAT)
• UnitedHealth cyberattack impedes pharmacies’ and hospitals’ ability to process insurance claims (STAT)
• Bipartisan group of lawmakers opposes Biden's plan to use 'march-in' to lower drug prices (Endpoints)
• What Alabama ruling means for patients with frozen embryos: one woman's story (Reuters)
• Oncopeptides’ Pepaxto Withdrawal Speeds Through In 7 Months Under Expedited Procedures (Pink Sheet)
• In Washington, The Answer Is Drug Shortages But What Is The Question? (Pink Sheet)

• Uzbek court sentences 23 over contaminated cough syrup deaths (Reuters)
• US hospital chain Providence Health bulks up India services unit to tap more clients (Reuters)
• EMA Addresses Need For Guideline On Antivirals & MAbs For COVID-19 (Pink Sheet)
• Travere's Filspari, J&J's Carvykti win support from CHMP in blitz of positive recommendations (Fierce Pharma)
• NICE Recommends Endoscopic Sleeve Gastroplasty To Treat Obesity (MedTech Insight)
• New EU Regulation Extending IVD Deadlines Expected In April (MedTech Insight)

• Human reproductive cloning: The curious incident of the dog in the night-time (STAT)
• Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH (STAT) (Endpoints) (Reuters)
• Ocular Therapeutix moves in the right direction, and Alnylam tries to calm some nerves (STAT)
• Gilead bid against itself in $4.3B deal for CymaBay, filing shows (Endpoints)
• Teva and Alvotech's interchangeable Humira biosimilar joins the party (Endpoints)
• AbbVie’s next CEO; $100B club refresh; Top 100 VCs, 2023; More hope for CAR-T in autoimmune; and more (Endpoints)
• GSK’s antibiotic succeeds in late-stage gonorrhea trial with eye to addressing resistance (Endpoints)
• Clade Therapeutics cuts staff and appears to shut down European subsidiary (Endpoints)
• Roche's Xolair reduces reactions to severe food allergies in study (Reuters)
• Venatorx, Melinta's BARDA-funded antibiotic combo falls short with manufacturing-related rejection (Fierce Pharma)
• To BioMarin CEO Alexander Hardy, hemophilia A gene therapy Roctavian needs 3 stars to align (Fierce Pharma)
• TL1A Inhibitors Could Usher in New Era for IBD Treatment (BioSpace)

• New GT Medical CEO Per Langoe on driving adoption of brain tumor therapy (MedTech Dive)
• FDA warns against using smart wearables that claim to measure blood sugar (MedTech Dive)
• 3M to spin off health unit April 1 (MedTech Dive)
• Canary Speech’s Voice AI Can Help Detect Alzheimer’s With 40-Second Conversation (MedTech Insight)
• FDA Guidance Doc Would Waive Registration Fees For Bankrupt Small Businesses (MedTech Insight)

• FDA Knows Its Own Strength—and It Includes Concentration (FDA Law Blog)
• Gilead settles with Maryland distributor over alleged counterfeit HIV drugs (Endpoints)
• Lilly’s ‘High Quality’ Donanemab Data Supports Unrestricted Medicare Coverage, Firm Says (Pink Sheet)